Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 17/20 | 0.57 |
| ▸ | CCNB1 | P14635 | 17/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 16/20 | 0.57 |
| ▸ | CDK2 | P24941 | 16/20 | 0.57 |
| ▸ | CCNA1 | P78396 | 16/20 | 0.57 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.56 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.56 |
| ▸ | MGMT | P16455 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7981045 | 1.00 | CDK1 (0.57) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8075242 | 1.00 | CDK1 (0.57) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8072893 | 0.90 | CDK1 (0.48) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8076767 | 0.77 | CDK1 (0.50) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8069356 | 0.76 | CDK1 (0.69) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL6263155 | 0.75 | CA2 (0.37) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL6266042 | 0.73 | CDK2 (1.00) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL10471471 | 0.72 | CCNK (0.38) | CDK2 | |
| SCHEMBL3462331 | 0.72 | CDK2 (1.00) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8618498 | 0.72 | CDK1 (0.77) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1746889-B1 | PLANT GROWTH REGULATION | BAYER CROPSCIENCE AG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080039321-A1 | Plant Growth Regulation | BAYER CROPSCIENCE AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-6303618-B1 | ADMINISTERING PURINE COMPOUND WHICH INHIBITS CYCLIC DEPENDENT KINASE ACTIVITY FOR THERAPY OF TUMOR OR OTHER CELL PROLIFERATION DISORDER | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039321-A1 | Plant Growth Regulation | OSR1, PPP6R3, PPP6R1 | CDK1 1909/4885CCNB1 811/4885CCNA2 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.